DECISION DIAGNOSTICS CORP - DECN STOCK NEWS

Decision Diagnostics Corp. (OTC PINK:DECN) has successfully completed testing for the XPRIZE Rapid Covid Testing competition, yielding results in 4-9 seconds that align with FDA lab testing on human donor saliva. The company’s GenViro! Swift Kits were tested using simulated samples as part of the $5 million competition to develop rapid, affordable Covid-19 testing solutions. Results submitted to the XPRIZE committee are expected to influence upcoming announcements on December 8. The company aims to revolutionize testing to meet increased demand amid the ongoing pandemic.

Decision Diagnostics Corp. (DECN) has signed distribution agreements for its GenViro! Covid-19 testing kits in Nigeria, Ivory Coast, and Lebanon. This progress coincides with ongoing testing at a Pennsylvania-based FDA and CLIA certified lab, as the company prepares for further FDA submissions. CEO Keith Berman noted increased interest from potential international distributors and existing partners for future Amazon listings. However, the GenViro! kits are not yet available in the U.S. as Emergency Use Authorizations (EUAs) are still pending.

Decision Diagnostics Corp. (OTC PINK:DECN) has commenced its donor study for the Genviro! Saliva Swift Kit, aimed at detecting Covid-19. This study is key for seeking FDA Emergency Use Authorization (EUA), EU CE Mark, and approvals in the Russian Federation. The company is confident that the saliva testing method will offer less invasive and more accurate results than previous blood tests. The results will support submissions to various regulatory bodies, with plans for completion in Q4.

Decision Diagnostics Corp. (OTC PINK:DECN) has announced significant developments concerning its GenViro! Covid-19 Saliva Swift Kit. The company signed an agreement with an FDA-certified testing partner to conduct necessary testing for FDA EUA approval, expected to be filed in Q4 2020. Additionally, DECN received a substantial purchase order from an Indian distributor for over 500,000 kits. They are also advancing in the XPRIZE competition aimed at improving rapid Covid testing. Alongside this, two professional instructional videos have been completed to assist users.

Decision Diagnostics Corp (OTC PINK: DECN), through its subsidiary Pharma Tech Solutions, has announced a new $300,000 8% Promissory Note with a major investor. The note's principal and interest will be payable in six months, with no conversion rights included. Previously, the company launched the international version of its GenViro! Swift Kit for Covid-19 testing and secured an order for 550,000 kits from an international distributor. Currently, the GenViro! product awaits emergency waiver determinations for U.S. availability.

Decision Diagnostics Corp. (OTC PINK: DECN) has received its first substantial purchase order from an Indian distributor, exceeding initial expectations. The order includes 500,000 GenViro! Saliva Swift Kits, 50,000 GenViro! Swift Verify Kits, and 7,500 Swift Kit Meters. Anticipated follow-up orders from distributors in Singapore and Malaysia are expected soon. The company is also pursuing Emergency Use Authorization with the U.S. FDA for its Covid-19 testing kits, which are designed for international markets and expected to enhance global presence.

Decision Diagnostics Corp. (OTC PINK:DECN) has partnered with a FDA & CLIA certified laboratory to initiate testing for the Genviro! Saliva Swift Kit. The results are expected to facilitate applications for FDA Emergency Use Authorization and European Union CE Mark certification, as well as submissions in the Russian Federation. The company aims to expedite market entry, with preliminary international orders already received. Moreover, DECN is participating in the XPRIZE Rapid Covid Testing competition in Korea, aiming for recognition in November 2020.

Decision Diagnostics Corp. (OTC PINK: DECN) has announced the completion of two professional use instructional videos for its Genviro! Covid-19 Saliva Swift Kit. These videos aim to ensure accurate testing results and will accompany the product's international launch on September 26, 2020. The instructional content will be available in English and several other languages, including German, Russian, Spanish, and French. The Genviro! Kit has already undergone rigorous testing in South Korea, and the company is seeking EUA waivers from the U.S. FDA.

Decision Diagnostics Corp. (OTC PINK: DECN) is preparing to launch its Covid-19 Saliva Swift Kits internationally, with a target date of September 26, 2020. The kits have undergone rigorous testing in South Korea and will include three products with varying wholesale and MSRP prices ranging from $6.95 to $29.95. The company is currently in the final stages of development, emphasizing efficiency and multiple testing capabilities. However, US availability is pending FDA authorization, as Emergency Use Authorization requests are in process.